Adele sells BMRN 57.7: BioMarin Announces Health Canada Approval of VIMIZIM(TM) (elosulfase alfa) for the Treatment of Morquio A Syndrome
TORONTO, Jul 7, 2014 (Canada NewsWire via COMTEX) -- Approval delivers first pharmaceutical therapy for children and adults with ultra-rare, life-limiting disorder BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that Health Canada has approved . ... ...
38 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home